Free tool
FAERS Monitor: Fotivda
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 212904 or its brand name (Fotivda, Tivozanib Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
1,610
Serious
603
37% of reports
Hospitalization
368
Death reported
159
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue316
- diarrhoea196
- blood pressure increased150
- nausea142
- disease progression139
- decreased appetite135
- dysphonia112
- death106
- asthenia93
- off label use93
- hypertension83
- vomiting73
- pain71
- dyspnoea70
- headache55
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 6 |
| 2012 | 2 |
| 2013 | 14 |
| 2014 | 2 |
| 2015 | 1 |
| 2017 | 2 |
| 2018 | 5 |
| 2019 | 9 |
| 2020 | 5 |
| 2021 | 349 |
| 2022 | 581 |
| 2023 | 230 |
| 2024 | 75 |
| 2025 | 209 |
| 2026 | 120 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,549 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| dysphoniaSignal | 112 | 25.1 | 21.0 | 2,566 |
| disease progressionSignal | 139 | 15.4 | 13.1 | 1,861 |
| blood pressure increasedSignal | 150 | 12.8 | 11.0 | 1,634 |
| decreased appetiteSignal | 135 | 7.6 | 6.5 | 775 |
| fatigueSignal | 316 | 5.3 | 4.8 | 1,141 |
| hypertensionSignal | 83 | 5.1 | 4.2 | 274 |
| diarrhoeaSignal | 196 | 4.0 | 3.5 | 446 |
| astheniaSignal | 93 | 3.2 | 2.7 | 144 |
| nauseaSignal | 142 | 2.3 | 2.0 | 112 |
| vomitingSignal | 73 | 2.0 | 1.6 | 38 |
| dyspnoea | 70 | 1.6 | 1.3 | 16 |
| death | 106 | 1.6 | 1.3 | 25 |
| pain | 71 | 1.5 | 1.2 | 12 |
| off label use | 93 | 1.4 | 1.1 | 10 |
| headache | 55 | 1.1 | 0.9 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.